A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers

Bioequivalence Clinical Trial

Official title:

A Randomized, Open-label, Crossover Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets Produced by Two Different Processes in Healthy Chinese Male Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03860948
• Other study ID #: 2018-504-00CH1
• Status: Completed
• Phase: Phase 1
• Start date: April 16, 2019
• Est. completion date: May 14, 2019

Study information

• Verified date: February 2019
• Source: Hutchison Medipharma Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, randomized, open lebal, single-dose, three-period, crossover clinical study in healthy Chinese male subjects to assess the pharmacokinetics and bioequivalence/bioavailability of two formulation savolitinib tablets.

Description:

Thirty six Chinese male subjects who met the inclusion criteria but not met the exclusion criteria, will be hospitalized in Phase I Ward one day before first dosing and randomized into three groups, 12 subjects each, at a ratio of 1:1:1. The subjects in the different group will follow the fixed dosing regimen with 600 mg savolitinib tablets (200 mg/tablet x 3 tablets) after the standard meal on day 1 in cycle 1, 2 and 3 respectively: TRR, RTR or RRT, where "T" indicates dry granulation savolitinib tablet and "R" indicates wet granulation savolitinib tablet. PK blood samples, 2 mL each time, will be collected at the following time points in each dosing cycle: within 0.5 hours before dosing and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 24, 36, 48 hours after dosing(16 time-points).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: May 14, 2019
• Est. primary completion date: May 2, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

1. Subjects must agree to comply with the protocol and Informed consent must be obtained in writing for all subjects;

2. Healthy male subjects aged 18 to 45 years inclusive at the time of screening;

3. Weight = 50 kg, body mass index (BMI) of 19-26 kg/m2;

4. No clinically significant abnormalities or findings in medical history, vital signs, physical examination, 12-lead ECG and laboratory values;

5. Males with the ability to have children must commit to adopting reliable contraceptive measures (e.g. condoms, contraceptive sponges, contraceptive gels, contraceptive films, intrauterine devices, contraceptives for oral or injectable intake, subcutaneous implants or other contraceptives) in collaboration with their partners for the duration of the study and for three months after the final dosage.

Exclusion Criteria:

1. History or symptoms of a clinically significant illness in metabolic/ endocrine, liver, kidney, blood, lung, immune system, cardiovascular, gastrointestinal, genitourinary, neurological, or psychiatric systerm in the 3 months before the study, as determined by the investigator;

2. History of gastrointestinal surgery, kidney surgery and cholecystectomy, which may potentially affect the absorption or excretion of drugs, as determined by the investigator ;

3. History of a severe allergy (for example, certain drug allergy) and acute allergic rhinitis or food allergy within 2 weeks prior to the screening stage;

4. Serum albumin < 35 g/L;

5. Hypertention: systolic blood pressure =140mmHg or diastolic blood pressure =90mmHg

6. Mean corrected QT interval (QTcF) in electrocardiograms (ECG), males > 450 milliseconds, or existing factors that may increase the risk of QTc prolongation, such as chronic hypokalemia that cannot be corrected by potassium supplementation, or congenital or familial long QT syndrome or a family history of unexplained sudden death under 40 years of age in first-degree relatives, or use any combination of drugs known to prolong the QT interval and cause torsades de pointes.

7. Clinical significant abormal findings in Chest X-ray (posteroanterior position) examination;

8. Serum virology positive findings, including HBS Ag, HCV Ab, HIV Ab, or TP Ab;

9. Current smoker of more than 10 cigarettes or equivalent / day during past 3 month prior to commencing the study and unable to completely stop smoking during the study;

10. Have blood or blood products transfusion within 2 months; or blood donation of more than 250 mL within 1 month or 400 mL within 3 months prior to screening; or planning to donate blood or blood components during the study or within 1 month after the end of the study;

11. History of alcohol abuse or drug addiction within one year prior to screening;

12. Participation in any other investigational drug clinical study while last dose was administrated within three months prior to the screening.

Related Conditions & MeSH terms

• Bioequivalence

Intervention

Drug:
• Savolitinib Test Preparation
Test preparation (T): dry granulation savolitinib tablets.
• Savolitinib Reference Preparation
Reference preparation (R): wet granulation savolitinib tablets.

Locations

Country	Name	City	State
China	Shanghai Xuhui District Central Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Hutchison Medipharma Limited

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The area under the curve(AUC) of savolitinib	The area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration.	Measured on the Cycle1 Day1 to Day3, Cycle2 Day1 to Day3, Cycle3 Day1 to Day3, each cycle is 10 days.
Primary	Maximum observed plasma concentration (Cmax) of savolitinib	Maximum observed concentration, occurring at Tmax.	Measured on the Cycle1 Day1 to Day3, Cycle2 Day1 to Day3, Cycle3 Day1 to Day3, each cycle is 10 days.
Primary	The time to Cmax (peak time, Tmax) of savolitinib	The time at which maximum plasma concentration (Cmax) is observed.	Measured on the Cycle1 Day1 to Day3, Cycle2 Day1 to Day3, Cycle3 Day1 to Day3, each cycle is 10 days.
Primary	Half-life (t1/2) of savolitinib	The time required for the concentration of the drug to reach half of its original value.	Measured on the Cycle1 Day1 to Day3, Cycle2 Day1 to Day3, Cycle3 Day1 to Day3, each cycle is 10 days.
Primary	Bioequivalence of savolitinib	A term in pharmacokinetics used to assess the expected in vivo biological equivalence of two proprietary preparations of a drug.	Measured on the Cycle1 Day1 to Day3, Cycle2 Day1 to Day3, Cycle3 Day1 to Day3, each cycle is 10 days.
Secondary	To observe the safety of healthy volunteers after a single oral dose of savolitinib	Incidence of adverse events evaluated by NCI CTCAE v4.03	From the first dose to within 12 days after the last dose
Secondary	Relative bioavailability of savolitinib	The area under the curve (AUC) is the definite integral in a plot of drug concentration in blood plasma vs. time.	Measured on the Cycle1 Day1 to Day3, Cycle2 Day1 to Day3, Cycle3 Day1 to Day3, each cycle is 10 days.